Retatrutide50mg Top Fat Burning Peptides Therapy Lyophilized 10mg/Vial Peptides Powder GLP-1

Description

Name:Lucky

Whatsapp:+852 60102064

Email Address:lucky25252587@gmail.com

Retatrutide (retatrutide/retatrutide) is an innovative therapeutic drug. The following is a detailed introduction to it:

English name: Retatrutide
Article Title: Retarglutide/Rataglutide
CAS number: 2381089-83-2
Drug type: glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP-1)/glucagon (GCG) triple receptor agonist

Retatrutide is a unique triple receptor agonist that can simultaneously activate the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR).

• GLP-1R agonism: After stimulating GLP-1R, it can promote insulin secretion and inhibit glucagon release, thereby lowering blood sugar levels. It can also delay gastric emptying, allowing users to feel full and reduce appetite.

• GIPR agonism: Activating GIPR can enhance the secretion of insulin and further help lower blood sugar.

• GCGR agonism: The agonistic effect on GCGR can promote fat decomposition and energy metabolism, which helps achieve weight loss goals. This multiple mechanism of action works together to make Retatrutide show great potential in weight management, blood sugar control, and overall metabolic health regulation.

Mechanism of action

• GLP-1R agonism: Stimulation of GLP-1R can promote insulin secretion and inhibit glucagon release, thereby lowering blood sugar levels. It can also delay gastric emptying, making users feel full and reducing appetite.

• GIPR agonism: Activating GIPR can enhance the secretion of insulin and further help lower blood sugar.

• GCGR agonism: The agonism of GCGR can promote fat decomposition and energy metabolism, which helps achieve weight loss goals. This multiple mechanism of action works together to make Retatrutide show great potential in weight management, blood sugar control and overall metabolic health regulation.

Clinical trial results

Weight loss effect: In phase 2 clinical trials, Retatrutide demonstrated significant weight loss effects. Obese patients lost more than 24% of their body weight after 48 weeks of treatment with Retatrutide. Among them, patients taking 8mg and 12mg doses lost at least 5% of their weight, and the weight loss effect of the high-dose group (12mg) was more significant.
Hypoglycemic effect: After 6 months of treatment with different doses of Retatrutide in patients with type 2 diabetes, glycated hemoglobin (HbA1c) decreased by 1.3%\~2.0%.
Safety: The safety and tolerability profile of Retatrutide is similar to other receptor agonists. The most common adverse reactions are gastrointestinal reactions, such as nausea, diarrhea, vomiting and constipation, mostly mild to moderate. In addition, some patients experience symptoms of increased heart rate, but this usually resolves after 24 weeks.

Scope of application
Obesity treatment: As an auxiliary treatment to diet control and exercise, it is used for long-term weight management in adults who are obese or overweight and have at least one weight-related comorbidity.
Type 2 diabetes treatment: Helps patients with type 2 diabetes lower blood sugar and lose weight at the same time.

Storage conditions
Low temperature, non-hazardous chemical shipments.
Packed to the nearest milligram upon request.
It is recommended to store sealed and away from light at 2~8°C, and refrigerated at -15~0°C for long-term storage.

5mg/vial,10vials/box;

10mg/vial,10vials/box;

15mg/vial,10vials/box;

60mg/vial,10vials/box;

Customers can specify express delivery, such as: UPS/DHL, etc. (Default express delivery: our cooperative logistics company)